develop
new
therapeut
agent
coronaviru
caus
middl
east
respiratori
syndrom
mer
continu
imper
initi
merscov
epidem
contain
entir
public
health
measur
episod
case
continu
current
therapeut
agent
effect
treatment
merscov
although
multipl
strategi
propos
studi
screen
compound
three
differ
compound
librari
one
essenti
proteas
papainlik
proteas
pl
pro
use
fluorescencebas
enzymat
assay
follow
surfac
plasmon
reson
spr
direct
bind
analysi
hit
confirm
mode
inhibit
assay
competit
spr
studi
reveal
two
compound
competit
inhibitor
improv
upon
inhibitori
activ
best
hit
compound
small
fragment
librari
consist
fragment
screen
presenc
hit
compound
result
one
fragment
enhanc
ic
valu
best
hit
compound
molecular
dock
mmpbsa
bind
energi
calcul
use
predict
potenti
bind
site
provid
insight
design
synthesi
nextgener
compound
middl
east
respiratori
syndrom
coronaviru
merscov
first
document
found
challeng
control
previous
identifi
sever
acut
respiratori
syndrom
coronaviru
sarscov
emerg
nearli
decad
earlier
histori
current
therapeut
option
sar
mer
well
less
sever
infect
human
coronaviru
strain
recent
review
detail
briefli
follow
initi
identif
mer
spread
within
middl
east
beyond
case
continu
aris
sporad
basi
particularli
saudi
arabia
unit
arab
emir
also
major
outbreak
mer
south
korea
start
return
travel
spread
hospit
infect
total
peopl
die
travelrel
case
particularli
challeng
patient
travel
middl
east
present
flulik
pneumonialik
symptom
countri
unprepar
recogn
treat
mer
januari
report
confirm
case
mer
result
fatal
across
countri
continu
report
new
episod
case
mortal
rate
mer
much
higher
case
sar
approxim
camel
human
transmiss
appear
primari
sourc
infect
sever
studi
implic
bat
primari
reservoir
merscov
origin
although
effect
camel
vaccin
may
ultim
best
control
strategi
none
appear
like
near
futur
persontoperson
transmiss
occur
primarili
close
contact
healthcar
set
among
stricken
famili
member
although
therapeut
option
treatment
merscov
infect
subject
recent
review
continu
emerg
new
case
merscov
combin
high
fatal
rate
potenti
futur
viral
mutat
make
develop
effect
therapeut
continu
prioriti
multifunct
papainlik
proteas
pl
pro
isol
merscov
recogn
potenti
druggabl
therapeut
target
inhibit
viral
replic
addit
role
select
cleavag
viral
replicas
polyprotein
merscov
pl
pro
merspl
pro
shown
contribut
merscov
pathogen
via
deisgylas
deubiquitinas
activ
host
protein
recent
studi
underscor
flexibl
merspl
pro
interact
interferon
stimul
gene
product
multipl
speci
studi
identifi
new
small
molecul
inhibitor
pl
pro
highthroughput
screen
ht
compound
three
commerci
avail
compound
librari
includ
fdaapprov
drug
librari
en
rout
potenti
novel
therapeut
altern
futur
total
compound
three
screen
librari
fdaapprov
prestwick
maybridg
chembridg
librari
screen
merspl
pro
fluoresc
intens
base
enzymat
endpoint
assay
follow
ic
valu
determin
doserespons
overal
systemat
screen
process
summar
fig
compound
number
librari
list
tabl
primari
screen
done
duplic
use
tecan
liquid
handl
robot
zfactor
vari
averag
indic
high
qualiti
screen
campaign
replic
plot
percent
inhibit
duplic
data
shown
fig
also
illustr
good
qualiti
screen
total
primari
hit
compound
exhibit
greater
inhibit
compound
concentr
shown
red
squar
fig
care
examin
hit
compound
structur
compound
either
toxic
contain
reactiv
function
group
elimin
thirti
compound
cherrypick
retest
triplic
percent
inhibit
continu
enzymat
assay
base
upon
reproduc
percent
inhibit
result
compound
select
reorder
commerci
vendor
hit
valid
half
maxim
inhibitori
concentr
ic
valu
determin
repurchas
compound
doserespons
curv
two
best
compound
shown
fig
ic
valu
work
refer
inhibit
merspl
pro
proteas
activ
rather
inhibitori
activ
merscov
replic
ic
valu
compound
respect
reduc
number
hit
compound
ic
valu
known
enzymat
function
assay
alon
bias
select
true
posit
hit
consequ
twelv
select
compound
subject
direct
bind
analysi
merspl
pro
enzym
surfac
plasmon
reson
spr
valid
spr
sensorgram
compound
seri
increas
concentr
shown
fig
exampl
compound
possess
slow
associ
slow
dissoci
rate
respect
result
bind
affin
k
suggest
bind
may
control
gate
mechan
initi
compound
seven
show
direct
bind
merspl
pro
protein
vari
rang
bind
affin
k
seven
compound
k
valu
compar
ic
valu
within
rang
fig
seven
valid
hit
two
compound
came
librari
fdaapprov
drug
pranlukast
compound
sulfasalazin
compound
pranlukast
cysteinyl
leukotrien
antagonist
use
antagon
bronchospasm
caus
allerg
reaction
allergen
asthmat
patient
sulfasalazin
use
treat
multipl
diseas
includ
rheumatoid
arthriti
crohn
diseas
ulcer
coliti
two
hit
compound
divers
set
maybridg
librari
chembridg
librari
produc
three
hit
compound
character
potenti
mechan
inhibit
lead
compound
ie
enzymat
mode
inhibit
studi
carri
vari
inhibitor
substrat
concentr
best
fit
model
determin
competit
inhibit
compound
ki
valu
respect
dixon
plot
shown
fig
exampl
ic
valu
determin
util
fix
substrat
concentr
remain
similar
differ
significantli
ki
valu
list
substrat
inhibitor
concentr
vari
fig
appear
compound
inhibit
merspl
pro
higher
substrat
concentr
may
suggest
substrat
compet
compound
easier
compound
confirm
competit
spr
k
valu
compound
alon
respect
presenc
substrat
bind
compound
complet
abolish
compound
weaker
fig
indic
substrat
compet
compound
compound
easili
substitut
substrat
compound
agreement
enzymat
assay
result
compound
exhibit
similar
inhibitori
activ
bind
affin
merspl
pro
howev
suitabl
lead
candid
optim
lower
molecular
weight
also
lower
ki
valu
henc
compound
select
character
includ
revers
studi
addit
observ
dissoci
fig
revers
compound
investig
via
three
differ
method
dialysi
desalt
dilut
complet
inhibit
merspl
pro
enzym
compound
inhibit
control
sampl
dmso
dialyz
overnight
order
remov
compound
recov
enzym
activ
unfortun
activ
activ
enzym
control
complet
lost
dialysi
second
util
desalt
column
remov
compound
also
result
deactiv
activ
control
sampl
thirdli
set
enzym
compound
high
concentr
gradual
dilut
activ
control
inhibit
sampl
exact
manner
measur
enzym
activ
dilut
step
compound
behav
irrevers
inhibitor
enzym
activ
recov
fulli
inhibit
howev
delet
enzym
activ
gradual
recov
provid
support
compound
revers
inhibitor
fig
interact
merspl
pro
compound
also
monitor
transvers
relax
optim
spectroscopi
trosi
n
nmr
spectra
use
uniformli
nlabel
histag
merspl
pro
fig
although
sequenti
assign
carri
apomerspl
pro
observ
thirteen
peak
either
shift
green
dot
box
arrow
disappear
green
solid
box
upon
compound
bind
merspl
pro
loss
n
reson
may
attribut
either
exchang
broaden
compound
bind
dissoci
conform
chang
merspl
pro
backbon
next
step
improv
inhibitori
activ
lead
compound
search
analog
four
analog
compound
shown
fig
commerci
avail
base
activ
five
structur
analogu
preliminari
structureact
relationship
sar
obtain
fig
core
function
new
lead
scaffold
benzen
sulfonamid
separ
sixmemb
nitrogencontain
ring
bound
sulfonamid
moieti
r
locat
highlight
blue
two
methyl
group
ortho
paraposit
better
inhibitori
activ
inhibit
inhibit
piperidin
inhibit
moieti
howev
unclear
either
methyl
heterocycl
core
crucial
mainten
activ
r
locat
shown
pink
amino
group
paraposit
benzen
essenti
activ
amino
group
replac
methyl
group
inhibitori
activ
decreas
significantli
inhibitori
activ
almost
complet
lost
inhibit
amino
group
acetyl
given
limit
number
structur
analog
preliminari
sar
simpli
underscor
key
structur
featur
integr
inhibitori
activ
none
test
commerci
analog
show
better
inhibitori
activ
merspl
pro
origin
lead
compound
led
us
screen
zenobia
small
fragment
librari
presenc
lead
compound
effort
increas
inhibitori
activ
fluorescencebas
enzym
assay
use
screen
zenobia
librari
attempt
search
addit
small
fragment
enhanc
inhibitori
activ
fragment
compound
fragment
exhibit
inhibit
inhibit
enhanc
concentr
presenc
compound
fragment
show
opposit
effect
decreas
inhibitori
activ
compound
probabl
compet
enzymat
bind
site
five
fragment
among
select
fragment
improv
appar
ic
valu
compound
improv
rang
better
tabl
ic
valu
fragment
alon
also
determin
without
compound
present
vari
significantli
fragment
exhibit
moder
enhanc
improv
ic
valu
compound
anoth
two
fragment
enhanc
inhibitori
activ
slightli
better
almost
interestingli
least
effect
fragment
best
activ
enhanc
compound
reduc
ic
valu
suggest
compound
might
inhibit
merspl
pro
addit
addit
bind
affin
compound
presenc
constant
concentr
determin
similar
compound
alon
suggest
probabl
bind
differ
locat
bind
site
fig
fig
also
show
readili
dissoci
merspl
pro
indic
bind
also
revers
compound
competit
inhibitor
merspl
pro
enzym
compet
substrat
catalyt
site
molecular
dock
perform
compound
catalyt
site
merspl
pro
three
differ
bind
pose
compound
select
shown
fig
order
investig
probabl
bind
pose
ns
molecular
dynam
simul
perform
three
conform
compound
bind
merspl
pro
follow
mmpbsa
bind
affin
calcul
use
packag
calcul
bind
energi
three
bind
pose
rang
kcal
mol
kcal
mol
tabl
pose
shown
cyan
fig
lowest
calcul
bind
energi
kcal
mol
among
three
potenti
bind
conform
correspond
rel
stabl
bind
interact
therefor
pose
select
probabl
bind
conform
compound
anoth
round
molecular
dock
md
simul
mm
pbsa
bind
affin
calcul
carri
predict
bind
pose
addit
fragment
dock
perform
radiu
area
around
compound
bind
keep
posit
compound
constant
fragment
dock
two
differ
bind
pose
obtain
gold
fig
ns
md
simul
mmpbsa
calcul
perform
ternari
complex
merspl
pro
compound
use
paramet
use
determin
bind
pose
compound
bind
energi
compound
improv
addit
kcal
mol
comparison
compound
bind
alon
kcal
mol
hand
bind
show
opposit
effect
decreas
overal
bind
energi
kcal
mol
therefor
select
probabl
bind
conform
mmpbsa
bind
energi
calcul
led
us
choos
compound
merspl
pro
overal
merspl
pro
enzym
structur
potenti
bind
pose
compound
shown
fig
carbonyl
group
compound
could
form
hbond
sidechain
residu
could
also
form
hbond
two
phenol
hydroxyl
pink
circl
fig
henc
may
play
import
role
bind
compound
meanwhil
sidechain
could
also
form
hbond
one
phenol
hydroxyl
fragment
compound
addit
mani
hydrophob
interact
surround
residu
also
import
bind
compound
fig
base
synergi
effect
fragment
compound
well
predict
bind
conform
design
candid
structur
moieti
compound
via
appropri
linker
futur
synthesi
fragmentlink
strategi
involv
replac
sulfonyl
group
chiral
carbon
get
link
extend
posit
compound
introduc
flexibl
linker
proper
length
import
keep
bind
pose
compound
two
atom
three
atom
four
atom
linker
alkyl
ester
group
newli
introduc
chiral
carbon
compound
use
molecular
dock
studi
carri
new
compound
differ
linker
verifi
structur
recapitul
key
bind
featur
compound
fragment
molecular
dock
result
two
carbon
linker
appear
inadequ
proper
bind
moieti
fig
therefor
extend
linker
three
four
atom
compound
fig
c
fragment
moieti
match
better
twocarbon
linker
compound
provid
better
direct
futur
compound
synthesi
also
highlight
interact
contribut
inhibitor
bind
although
repurpos
hiv
proteas
inhibitor
lopinavirritonavir
found
somewhat
effect
merscov
could
backup
treatment
mer
develop
specif
inhibitor
target
merscov
still
need
report
new
small
molecul
scaffold
effect
competit
inhibitor
merspl
pro
scaffold
identifi
screen
three
structur
divers
compound
librari
includ
fdaapprov
drug
librari
call
prestwick
thorough
hit
valid
confirm
strategi
appli
produc
two
lead
compound
moder
inhibitori
activ
bind
affin
two
compound
character
competit
inhibitor
base
enzymat
mechan
inhibit
competit
spr
studi
one
select
better
lead
candid
character
develop
due
lack
commerci
avail
analog
lead
compound
limit
preliminari
sar
obtain
henc
explor
fragmentlink
strategi
improv
lead
compound
activ
addit
small
fragment
librari
screen
presenc
lead
compound
produc
addit
fragment
enhanc
ic
valu
lead
compound
molecular
dock
mm
pbsa
bind
energi
calcul
perform
predict
potenti
bind
site
compound
provid
direct
futur
design
fragmentlink
inhibitor
improv
potenc
develop
inhibitor
merspl
pro
screen
three
commerci
avail
compound
librari
purchas
fdaapprov
prestwick
maybridg
chembridg
librari
consist
compound
respect
compound
dissolv
dmso
store
mm
stock
solut
desicc
condit
primari
ht
assay
perform
tecan
freedom
evo
robot
equip
temo
liquid
handler
dispens
stainless
steel
pin
tool
v
p
scientif
nl
capillari
capac
assay
done
duplic
black
plate
matrix
technolog
room
temperatur
merspl
pro
enzym
purifi
describ
prepar
assay
buffer
mm
hepe
ph
triton
vv
mg
ml
bsa
mm
dtt
enzym
solut
nm
final
concentr
dispens
well
nl
mm
compound
final
concentr
ad
incub
min
enzym
reaction
initi
ad
substrat
zargleuargglyglyamc
bachem
bioscienc
final
concentr
dissolv
assay
buffer
incub
min
enzym
reaction
stop
ad
sd
stop
solut
fluoresc
intens
monitor
nm
excit
nm
emiss
tecan
genio
pro
micropl
reader
plate
contain
total
posit
neg
control
structur
initi
hit
compound
ht
examin
cherrypick
reanalyz
continu
kinet
assay
hand
confirm
show
inhibit
concentr
confirm
assay
ic
valu
measur
use
assay
condit
primari
screen
hand
triplic
seri
increas
concentr
final
concentr
serial
dilut
dmso
prepar
plate
nm
enzym
solut
distribut
well
vari
concentr
compound
ad
incub
min
enzym
reaction
initi
ad
substrat
activ
continu
monitor
least
min
ic
valu
calcul
fit
data
hill
equat
use
sigmaplot
percent
inhibit
x
inhibitor
concentr
n
slope
concentrationrespons
curv
hill
slope
v
max
maxim
inhibit
three
four
independ
assay
merspl
pro
enzym
dilut
mm
sodium
acet
ph
immobil
sensor
chip
standard
aminecoupl
run
buffer
pbsp
mm
phosphat
ph
mm
kcl
mm
nacl
surfact
use
biacor
instrument
merspl
pro
enzym
immobil
flow
cell
immobil
level
ru
flow
cell
unmodifi
flow
cell
use
control
compound
solut
seri
increas
concentr
dilut
appli
four
channel
spr
bind
buffer
pbsp
mm
tcep
dmso
flow
rate
data
doublereferenc
refer
cell
ru
valu
zero
concentr
dmso
signal
sensorgram
analyz
use
biacor
evalu
softwar
respons
unit
concentr
measur
equilibr
phase
steadyst
affin
fit
k
valu
determin
fit
data
singl
rectangular
hyperbol
curv
eq
respons
max
maximum
respons
x
compound
concentr
kinet
rate
constant
determin
fit
global
langmuir
model
embed
biacor
evalu
softwar
enzymat
activ
merspl
pro
investig
way
ic
valu
determin
vari
concentr
substrat
inhibitor
data
fit
four
equat
use
sigmaplot
enzym
kinet
modul
order
determin
best
fit
inhibit
mechan
kinet
paramet
compound
v
reaction
rate
v
max
maximum
rate
reaction
k
michaelismenten
constant
substrat
substrat
concentr
inhibitor
concentr
k
dissoci
constant
inhibitor
free
enzym
dissoci
constant
inhibitor
es
complex
merspl
pro
incub
compound
concentr
ic
h
room
temperatur
assay
buffer
contain
mm
hepe
ph
mm
dtt
mgml
bsa
triton
final
volum
control
merspl
pro
without
compound
also
prepar
way
volum
dmso
sampl
dilut
use
assay
buffer
supplementari
fig
merspl
pro
enzym
activ
sampl
measur
seven
addit
dilut
done
follow
enzym
activ
measur
merspl
pro
activ
measur
way
ic
measur
zenobia
fragment
librari
consist
compound
screen
similar
way
primari
ht
origin
stock
concentr
fragment
mm
dissolv
dmso
dilut
mm
dmso
compound
ad
assay
buffer
final
concentr
screen
well
posit
neg
control
contain
amount
dmso
enzym
solut
nm
final
concentr
dispens
well
nl
mm
fragment
final
concentr
ad
incub
min
enzym
reaction
initi
substrat
final
concentr
dissolv
assay
buffer
incub
min
enzym
reaction
continu
monitor
min
nm
excit
nm
emiss
tecan
genio
pro
micropl
reader
crystal
structur
merspl
pro
complex
ubiquitin
pdb
code
resolut
select
perform
molecular
dock
merspl
pro
structur
optim
protein
prepar
wizard
suit
hydrogen
charg
ad
forc
field
restrain
minim
perform
ad
hydrogen
meanwhil
ligprep
modul
suit
use
creat
structur
compound
well
perform
geometr
optim
molecular
dock
perform
gold
use
prepar
merspl
pro
compound
ubiquitin
extract
perform
dock
activ
site
merspl
pro
defin
within
radiu
around
catalyt
residu
dock
compound
merspl
pro
maintain
static
compound
flexibl
flip
amid
bond
detect
intern
h
bond
flip
ring
corner
set
ligand
conform
search
paramet
appli
default
valu
gold
three
differ
bind
pose
compound
chosen
follow
md
simul
subsequ
mmpbsa
calcul
predict
bind
affin
use
suit
program
prepar
md
simul
includ
assign
restrain
electrostat
potenti
resp
atom
partial
charg
compound
use
gaussian
red
onlin
server
assign
gener
amber
forc
field
gaff
paramet
prepar
ligand
octahedr
water
molecul
box
ad
complex
system
use
clcounterion
neutral
system
amber
forc
field
appli
system
system
first
minim
use
step
steepest
descent
minim
follow
anoth
step
conjug
gradient
minim
heat
k
k
ps
system
equilibr
ps
constant
pressur
bar
temperatur
k
restraint
kcal
mol
complex
subsequ
without
restraint
ns
npt
product
run
without
posit
restraint
perform
k
bar
system
atom
coordin
save
everi
ps
md
simul
bond
involv
hydrogen
atom
constrain
equilibrium
distanc
use
shake
algorithm
time
step
fs
python
script
mmpbsapi
includ
amber
use
perform
mmpbsa
calcul
use
frame
last
ns
ns
simul
fig
design
compound
fragment
link
strategi
predict
bind
pose
among
three
design
compound
synthesi
two
compound
nearli
recapitul
bind
pose
compound
molecular
dock
linker
color
red
structur
compound
color
sky
blue
color
dark
blue
merspl
pro
enzym
shown
grey
surfac
trajectori
file
default
paramet
appli
bind
affin
calcul
bind
site
fragment
select
around
predict
bind
posit
compound
dock
two
differ
bind
pose
pick
perform
subsequ
ns
md
simul
bind
energi
calcul
compound
consist
paramet
appli
md
simul
ternari
complex
merspl
pro
compound
binari
complex
merspl
pro
compound
order
compar
bind
affin
differ
compound
incorpor
nmr
spectra
uniformli
nlabel
histag
apomerspl
pro
presenc
absenc
excess
compound
record
bruker
mhz
nmr
spectromet
nmr
solut
contain
nlabel
histag
merspl
pro
mm
kh
po
ph
mm
kcl
mm
dtt
merspl
pro
excess
inhibitor
spectrum
gener
ad
four
equival
compound
dmso
apomerspl
pro
produc
aqueou
buffer
dmso
solut
gentli
vortex
transfer
mm
od
glass
nmr
tube
transvers
relax
optim
spectroscopi
trosi
n
spectrum
acquir
overnight
rt
sparki
util
process
nmr
data
produc
imag
